The new certification elevates recognition for pharmacies already holding a Specialty Pharmacy Accreditation and demonstrates enhanced performance standards caring for rare-disease populations. The review process for the new certification evaluates a pharmacy’s ability to provide comprehensive clinical management, coordinated care, patient education and operational excellence tailored to individuals living with rare conditions. 

“Patients with rare diseases often face complex treatment journeys requiring specialized clinical expertise, proactive coordination and hands-on support,” said Chelsea Hustad, Lumicera’s Clinical Services and Residency Program Director. “Earning URAC’s Rare Disease Pharmacy Center of Excellence Certification affirms the rigor of our clinical programs and the dedication of our teams ensuring that patients receive the highest levels of individualized, high-touch care.” 

Rare-disease patients frequently require advanced therapies, ongoing monitoring, coordination across multiple providers and support navigating financial and access barriers. Lumicera provides personalized care plans, clinical oversight, adherence support and close collaboration with prescribers and payers to optimize outcomes. 

This certification reinforces Lumicera’s broader specialty pharmacy strategy and commitment to advancing care for patients with complex and rare conditions. As demand grows for specialty and rare-disease therapies, Lumicera delivers clinically sound, patient-focused services that balance access, safety and sustainability.